Related references
Note: Only part of the references are listed.Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Anna He et al.
LANCET NEUROLOGY (2020)
Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis
Nathaniel Lizak et al.
JAMA NEUROLOGY (2020)
Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
Jacqueline Palace et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
The MSBase registry: Informing clinical practice
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis
Daniel Ontaneda et al.
LANCET NEUROLOGY (2019)
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis
Jordana Hughes et al.
JAMA NEUROLOGY (2018)
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study
Marcus D'Souza et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Data quality evaluation for observational multiple sclerosis registries
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Importance of early treatment initiation in the clinical course of multiple sclerosis
Andrius Kavaliunas et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study
Marcus D'Souza et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Data quality evaluation for observational multiple sclerosis registries
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Importance of early treatment initiation in the clinical course of multiple sclerosis
Andrius Kavaliunas et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Johannes Lorscheider et al.
NEUROLOGY (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis
Vilija G. Jokubaitis et al.
ANNALS OF NEUROLOGY (2016)
Observational data: Understanding the real MS world
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
Ludwig Kappos et al.
NEUROLOGY (2016)
Observational data: Understanding the real MS world
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Defining reliable disability outcomes in multiple sclerosis
Tomas Kalincik et al.
BRAIN (2015)
Robust Estimation of Inverse Probability Weights for Marginal Structural Models
Kosuke Imai et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2015)
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator
Jacqueline Palace et al.
LANCET NEUROLOGY (2015)
Predictors of disability worsening in clinically isolated syndrome
Vilija G. Jokubaitis et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Marginal Structural Cox Models for Estimating the Association Between β-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort
Mohammad Ehsanul Karim et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2014)
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome
Giancarlo Comi et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis
Afsaneh Shirani et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Progressive multiple sclerosis: pathology and pathogenesis
Hans Lassmann et al.
NATURE REVIEWS NEUROLOGY (2012)
Survival in MS A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial
D. S. Goodin et al.
NEUROLOGY (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS
Douglas S. Goodin et al.
PLOS ONE (2011)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alasdair J. Coles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
New natural history of interferon-β treated relapsing multiple sclerosis
Maria Trojano et al.
ANNALS OF NEUROLOGY (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
A definition of causal effect for epidemiological research
MA Hernán
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH (2004)
Marginal structural models for analyzing causal effects of time-dependent treatments: An application in perinatal epidemiology
LM Bodnar et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2004)
Estimating causal effects
G Maldonado et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2002)
Marginal structural models and causal inference in epidemiology
JM Robins et al.
EPIDEMIOLOGY (2000)
Share Paper
